Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AX 250 Extension Study in MPS IIIB
NCT05492799Phase 4Enrolling by invitation
- Sponsor
- Allievex
- Start
- Dec 2022
- Primary completion
- Oct 2027
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 4 trial of tralesinidase alfa in mucopolysaccharidosis type IIIB, sponsored by Allievex. Started Dec 2022; status: enrolling by invitation.
02
Drugs
tralesinidase alfa
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on NCT05492799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492799.